GLP-1 pills vs injections for weight loss: how they compare
Oral and injectable Wegovy use the same drug but differ in dosing, absorption, and convenience. Here is how the evidence compares for obesity treatment.
Obesity and brain health: how excess weight affects cognition and dementia risk
Sep 21, 2026
Hepcidin in polycythemia vera: how iron controls red blood cell production
Sep 20, 2026
Oral SERDs for breast cancer: how they differ from older endocrine therapy
Sep 20, 2026
How long does nirsevimab protect infants from RSV?
Sep 19, 2026The latest, in bite-sized science
Fresh discoveries and health headlines, curated from top journals and explained so anyone can follow.
Clinical Research & TrialsHow long does nirsevimab protect infants from RSV?
Nirsevimab is designed to cover an RSV season with one dose. Trials show protection for at least 5 months, with hospitalization protection through 180 days.
Read the Full Bite →
Clinical Research & TrialsBeyfortus dosing guide: what parents and clinicians should know
Beyfortus dosing changes by weight and RSV season. Here is when nirsevimab is given as 50 mg, 100 mg, or 200 mg and who is eligible.
Read the Full Bite →
Cell & Molecular BiologyTYK2 and JAK1 explained: how immune signaling becomes a drug target
TYK2 and JAK1 help cytokines activate the JAK-STAT pathway. Here is how selective inhibition differs from broader JAK blockade and why it matters in autoimmune disease.
Read the Full Bite →
Clinical Research & TrialsGLP-1 drugs and muscle loss: what the evidence really shows
Semaglutide and tirzepatide reduce lean mass during weight loss, but mostly reduce fat. Here is what DXA studies show about muscle, sarcopenia, and resistance training.
Read the Full Bite →
Cardiovascular Health2026 stroke rehabilitation guideline: what changed
The 2026 AHA/ASA stroke rehabilitation guideline emphasizes earlier therapy, mental health, caregiver support, telehealth, and repeated reassessment across recovery.
Read the Full Bite →
Cancer & OncologyCDK4/6 inhibitors explained: how they slow breast cancer growth
CDK4/6 inhibitors slow HR-positive breast cancer by blocking a cell-cycle checkpoint. Here is how palbociclib, ribociclib, and abemaciclib work and how resistance develops.
Read the Full Bite →Editor’s picks
Hand-picked bites we think are worth your time — whether you’re new here or returning.
PharmacologyGLP-1 drugs, explained: how they work, what they treat, and what’s next
GLP-1 drugs now treat far more than diabetes and weight. A clear guide to how they work, which are approved, how well they work, and what is coming next.
Read the Full Bite →
PharmacologyGLP-1 drugs: beyond weight loss
The blockbuster class started with diabetes and keeps finding new frontiers.
Read the Full Bite →
Vaccines & ImmunizationHow mRNA went from lab curiosity to household word
The technology behind COVID vaccines is now aimed at cancer and more.
Read the Full Bite →
Diabetes & MetabolismGLP-1 side effects: what is common and what needs attention
Nausea and other gastrointestinal symptoms are common with GLP-1-based medicines, while pancreatitis, gallbladder disease, dehydration, and other serious risks are less frequent.
Read the Full Bite →
Cardiovascular HealthStopping statins after 75: what a randomized trial found
In a randomized trial of adults 75 and older without prior heart disease or stroke, stopping statins did not increase deaths over three years, although LDL cholesterol rose sharply.
Read the Full Bite →
FDA ApprovedFDA approves Etcamah (camizestrant) for ESR1-mutated advanced breast cancer
Camizestrant plus a CDK4/6 inhibitor extended median progression-free survival from 9.2 to 16.0 months after an ESR1 resistance mutation emerged before imaging progression.
Read the Full Bite →Bridging research and reality
Bites of Bio breaks down complex ideas in health, medicine, and life sciences into short, digestible insights that anyone can understand. From new discoveries in top journals to expert insights across the web, we curate and simplify the best of biology — for students, professionals, patients, and the simply curious.
Our mission is to keep you informed, inspired, and connected to how biology shapes your everyday world. Every bite is evidence-based, jargon-free, and short enough to actually finish.
Explore the Topics →Story & mission
Started by a science communicator tired of watching great research get lost in dense PDFs and paywalls. Bites of Bio translates the signal — not the hype — into plain language you can trust and share.
What makes us different
We simplify without dumbing down. Every summary links back to primary sources, flags uncertainty honestly, and never turns a single study into a miracle cure.
FDA approvals, clearly explained
What each approved drug does, who it is for, and why it matters — minus the regulatory jargon.
FDA ApprovedFDA approves Imaavy, first treatment for warm autoimmune hemolytic anemia
Imaavy is the first FDA-approved treatment specifically for warm autoimmune hemolytic anemia.
Read the Full Bite →
FDA ApprovedFDA approves Tudriqev, an engineered viral immunotherapy for advanced melanoma
An engineered HSV-1 plus nivolumab won accelerated approval after PD-1 failure, despite major trial-design concerns.
Read the Full Bite →
FDA ApprovedFDA approves Inluriyo plus Verzenio for ESR1-mutated breast cancer
FDA approved Inluriyo plus Verzenio for ESR1-mutated advanced breast cancer after prior endocrine therapy.
Read the Full Bite →Free health & fitness calculators
Thirteen instant, private calculators — BMI, BMR, TDEE, body fat, macros, heart-rate zones and more — using standard published formulas.